{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:39:30Z","timestamp":1763037570842,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003186","name":"National Rosacea Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaad.2021.01.098","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T01:36:00Z","timestamp":1612488960000},"page":"1044-1046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial"],"prefix":"10.1016","volume":"85","author":[{"given":"Jerry","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna L.","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noori","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleh","family":"Rachidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hester","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina Sisto","family":"Alessi C\u00e9sar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sewon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A.","family":"Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2021.01.098_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","article-title":"Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies","volume":"166","author":"Fowler","year":"2012","journal-title":"Br J Dermatol"},{"issue":"suppl","key":"10.1016\/j.jaad.2021.01.098_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0039-6257(83)90138-8","article-title":"Shortterm \u201cescape\u201d and longterm \u201cdrift.\u201d The dissipation effects of the beta adrenergic blocking agents","volume":"28","author":"Boger","year":"1983","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jaad.2021.01.098_bib3","first-page":"354","article-title":"Restoring sensitivity to timolol after long-term drift in primary open-angle glaucoma","volume":"31","author":"Gandolfi","year":"1990","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaad.2021.01.098_bib4","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.jaad.2014.01.853","article-title":"Brimonidine effective but may lead to significant rebound erythema","volume":"70","author":"Ilkovitch","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.01.098_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/09546634.2019.1639606","article-title":"Difference in vasoconstrictors: oxymetazoline vs. brimonidine","volume":"32","author":"Okwundu","year":"2021","journal-title":"J Dermatolog Treat"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221003091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221003091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:02Z","timestamp":1759273262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221003091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0190962221003091"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.01.098","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.01.098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}